

Enhanced Annual Drug List Updates

July 2024

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
HEMLIBRA (emicizumab-kxwh subcutaneous soln 12 mg/0.4ml (30 mg/ml))	Brand	Addition, Preferred Status
HEMLIBRA (emicizumab-kxwh subcutaneous soln 300 mg/2ml (150 mg/ml))	Brand	Addition, Preferred Status
OMNIPOD 5 G6 INTRO KIT (GEN 5) (insulin infusion disposable pump kit)	Brand	Addition, Preferred Status
OMNIPOD 5 G6 PODS (GEN 5) (insulin infusion disposable pump reservoir)	Brand	Addition, Preferred Status
OMNIPOD 5 G7 INTRO KIT (GEN 5) (insulin infusion disposable pump kit)	Brand	Addition, Preferred Status
OMNIPOD 5 G7 PODS (GEN 5) (insulin infusion disposable pump reservoir)	Brand	Addition, Preferred Status
OMNIPOD DASH INTRO KIT (GEN 4) (insulin infusion disposable pump kit)	Brand	Addition, Preferred Status
OMNIPOD DASH PODS (GEN 4) (insulin infusion disposable pump reservoir)	Brand	Addition, Preferred Status
ROZLYTREK (entrectinib pellet pack 50 mg)	Brand	Addition, Preferred Status
VUMERITY (dioximel fumarate capsule delayed release 231 mg)	Brand	Addition, Preferred Status
XALKORI (crizotinib cap sprinkle 150 mg)	Brand	Addition, Preferred Status
XALKORI (crizotinib cap sprinkle 20 mg)	Brand	Addition, Preferred Status
XALKORI (crizotinib cap sprinkle 50 mg)	Brand	Addition, Preferred Status
XOLAIR (omalizumab subcutaneous soln auto-injector 150 mg/ml)	Brand	Addition, Preferred Status
XOLAIR (omalizumab subcutaneous soln auto-injector 300 mg/2ml)	Brand	Addition, Preferred Status
XOLAIR (omalizumab subcutaneous soln auto-injector 75 mg/0.5ml)	Brand	Addition, Preferred Status
XOLAIR (omalizumab subcutaneous soln prefilled syringe 300 mg/2ml)	Brand	Addition, Preferred Status
ZURZUVAE (zuranolone cap 20 mg)	Brand	Addition, Preferred Status
ZURZUVAE (zuranolone cap 25 mg)	Brand	Addition, Preferred Status
ZURZUVAE (zuranolone cap 30 mg)	Brand	Addition, Preferred Status

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent Licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Illinois (BCBSIL) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.